J&J launches Phase III trial of single-shot Covid-19 vaccine
The placebo-controlled trial, ENSEMBLE, will enroll up to 60,000 healthy volunteers on three continents. The trial will test the vaccine JNJ-78436735, also known as Ad26.COV2.S.
Ad26.COV2.S
J&J Initiates Global P-III Clinical Study of its COVID-19 Vaccine
Shots: The initiation of the ENSEMBLE trial follows positive interim results of P-I/IIa study demonstrating the safety and immunogenicity of JNJ-78436735 following a single vaccination. The results have been submitted to medRxiv and expected to be published imminently The P-III ENSEMBLE study is designed to… Read More »J&J Initiates Global P-III Clinical Study of its COVID-19 Vaccine
Johnson & Johnson Collaborates with the Government of Canada to Supply its Ad26.COV2.S for COVID-19
Shots: Janssen signs an agreement in principle with the Government of Canada to supply its COVID-19 vaccine, ensuring broad Canadian access to Ad26.COV2.S, following Health Canada’s approval In addition, a final agreement will be determined in due course under which the Government of Canada would… Read More »Johnson & Johnson Collaborates with the Government of Canada to Supply its Ad26.COV2.S for COVID-19
J&J in $1B supply pact with federal government for one-shot Covid-19 vaccine
Under the agreement with BARDA and the Department of Defense, the drugmaker would supply 100 million doses of its vaccine, for which it published preclinical data last and is currently running a first-in-human clinical trial.